




Pr. 1: High resolution tumor and immune cell profiling



Milestone 1 (yr 3): Identification of immune suppressive/exhaustion pathways to be harnessed in program 2 & 3

Milestone 2 (yr 4): Development of a library of tumor-specific TCRs and identification of new CAR targets in CRC and PDAC MTS


Pr. 2: Adoptive cell therapy with genetically engineered T-cells



Milestone 3 (yr 4): Generation & validation of innovative TCR and CAR T cell products to be implemented in clinical trials


Milestone 5 (yr 5): Identification of leading candidate immune cell-based combinatorial systems

Pr. 3: In vivo gene-based targeted cytokine delivery



Milestone 4 (yr 4): Identification of the leading candidate cytokine delivery system

Pr. 4: Toward clinical implementation



Milestone 6 (yr 6): Selection of ATMPs for clinical trial implementation

Program outcome : Novel ATMP(s) ready for clinical trial